Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RMTI 
Rockwell Medical Inc (RMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: RMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.75
1 Year Target Price $3.75
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.89% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.38M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 2 | Beta 1.62 | 52 Weeks Range 0.78 - 2.41 | Updated Date 12/12/2025 |
52 Weeks Range 0.78 - 2.41 | Updated Date 12/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.05 | Actual -0.05 |
Profitability
Profit Margin -7.3% | Operating Margin (TTM) -9.95% |
Management Effectiveness
Return on Assets (TTM) -5.25% | Return on Equity (TTM) -16.68% |
Valuation
Trailing PE - | Forward PE 59.17 | Enterprise Value 26793928 | Price to Sales(TTM) 0.49 |
Enterprise Value 26793928 | Price to Sales(TTM) 0.49 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 30.21 | Shares Outstanding 39405302 | Shares Floating 35237009 |
Shares Outstanding 39405302 | Shares Floating 35237009 | ||
Percent Insiders 12.41 | Percent Institutions 8.57 |
Upturn AI SWOT
Rockwell Medical Inc
Company Overview
History and Background
Rockwell Medical, founded in 1995, focuses on innovative solutions for kidney disease. It has evolved from a dialysis concentrate supplier to a pharmaceutical company addressing unmet needs in end-stage renal disease (ESRD).
Core Business Areas
- Drug Products: Includes Triferic (ferric pyrophosphate citrate) for iron deficiency anemia in hemodialysis patients.
- Dialysis Concentrates: Manufactures and distributes concentrates used in hemodialysis, offering both liquid and powder formulations.
Leadership and Structure
Dr. Mark Klausner serves as the President and CEO. The company has a standard organizational structure with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Triferic: Triferic is Rockwell Medical's key pharmaceutical product, intended to replace iron lost during hemodialysis and maintain hemoglobin levels. Market share data is not readily available. Competitors include intravenous iron therapies.
- Dialysis Concentrates: Rockwell Medical's concentrates are used in dialysis treatments. Market share data is not readily available. Competitors include Baxter International (BAX) and Fresenius Medical Care (FMS).
Market Dynamics
Industry Overview
The renal dialysis market is growing due to the increasing prevalence of kidney disease, driven by factors such as diabetes and hypertension. The market is consolidated with a few large players.
Positioning
Rockwell Medical positions itself as an innovator in renal care, particularly with Triferic. Its competitive advantage lies in its unique product offering that addresses iron deficiency without the risks associated with IV iron.
Total Addressable Market (TAM)
The global dialysis market is estimated to be in the tens of billions of USD. Rockwell Medical is positioned to capture a portion of this market through its products and services, but faces competition from larger players.
Upturn SWOT Analysis
Strengths
- Proprietary Triferic product
- Established presence in dialysis concentrate market
- Focus on unmet needs in ESRD
Weaknesses
- Reliance on Triferic sales
- Limited financial resources compared to larger competitors
- Dependence on regulatory approvals
Opportunities
- Expanding Triferic market share
- Developing new renal therapies
- Strategic partnerships and acquisitions
Threats
- Competition from established dialysis providers
- Pricing pressures from payers
- Regulatory changes
Competitors and Market Share
Key Competitors
- Baxter International (BAX)
- Fresenius Medical Care (FMS)
- DaVita Inc. (DVA)
Competitive Landscape
Rockwell Medical faces intense competition from larger, more established players. Its competitive advantage lies in its unique Triferic product, but it needs to overcome challenges related to market access and reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires access to financial statements and stock performance. Unavailable
Future Projections: Future Projections requires access to analyst estimates. Unavailable.
Recent Initiatives: Recent strategic initiatives require up-to-date company releases. Unavailable.
Summary
Rockwell Medical is a smaller player in a consolidated dialysis market, with its proprietary drug Triferic offering a unique value proposition. However, its reliance on Triferic and limited financial resources present challenges. Future success hinges on expanding Triferic's market share and navigating the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Information
- Industry Reports
- Financial News Articles
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It is not financial advice. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rockwell Medical Inc
Exchange NASDAQ | Headquaters Wixom, MI, United States | ||
IPO Launch date 1998-01-27 | President, CEO & Director Dr. Mark Strobeck Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 244 | Website https://www.rockwellmed.com |
Full time employees 244 | Website https://www.rockwellmed.com | ||
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.